Localized Scleroderma: A Clinical Review

Author(s): Mark Tratenberg, Farrah Gutwein, Varuni Rao, Kirk Sperber, Amy Wasserrman, Julia Ash*

Journal Name: Current Rheumatology Reviews

Volume 13 , Issue 2 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Localized scleroderma (LS) is characterized by excessive collagen deposition leading to thickening of the dermis, subcutaneous tissue or both. The outcome for most patients with localized scleroderma is directly related to the type and stage of the affected tissue. The major challenge for untreated patients is not increased mortality risk, rather deformity and growth defects from skin, muscle and bone abnormalities. Treatment is individualized to type and stage of the lesion and may include pharmacologic and non-pharmacologic therapies. Among the pharmacologic modalities, methotrexate with systemic glucocorticoids is currently the mainstay of treatment. More controlled trials are needed to determine the length of treatment and the maintenance dose of this combination therapy.

Keywords: Scleroderma, morphea, en-coup de sabre, linear, guttate, keloid, non-pharmacologic therapies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 06 September, 2016
Page: [86 - 92]
Pages: 7
DOI: 10.2174/1573397112666160907105434
Price: $65

Article Metrics

PDF: 48